SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine

References

• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–10. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. doi:10.3390/v12020135.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–42. doi:10.1001/jama.2020.2648.
   PubMed Web of Science ®Google Scholar
• Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44. doi:10.1038/s41564-020-0695-z.
   PubMed Web of Science ®Google Scholar
• KKMNOW. Department of statistics Malaysia, Ministry of health Malaysia. COVID -19. The latest data on the pandemic in Malaysia. [accessed 2023 June 17]. https://data.moh.gov.my/covid.
   Google Scholar
• Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20(6):339–41. doi:10.1038/s41577-020-0321-6.
   PubMed Web of Science ®Google Scholar
• Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, Yang X, Wang B, Chen L, Chen Q, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12(1):1813. doi:10.1038/s41467-021-22034-1.
   PubMed Web of Science ®Google Scholar
• Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. J Med Virol. 2020;92(5):512–7. doi:10.1002/jmv.25715.
   PubMed Web of Science ®Google Scholar
• Favresse J, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eeckhoudt S, David C, Morimont L, Dogné JM, Douxfils J. Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2. Viruses. 2021;13(7):1364. doi:10.3390/v13071364.
   PubMed Web of Science ®Google Scholar
• Daniel WW, Cross CL. Biostatistics: a foundation for analysis in the health sciences. Hoboken (NJ): Wiley; 2018.
   Google Scholar
• Ling HS, Pang IX, Fong AYY, Ong TK, Khiew NZ, Cham Y, Chen LS. Covid-19 antibody surveillance among healthcare workers in a non-covid designated cardiology centre. 2020. doi:10.22541/au.158955330.06881415.
   Google Scholar
• Statistics on Household Income & Basic Amenities. Ministry of economy, department of statis Malaysia, household income & basic amenities survey report 2019. [accessed 2022 Jan 3]. https://www.dosm.gov.my/portal-main/release-content/household-income-&-basic-amenities-survey-report-2019.
   Google Scholar
• Morales-Núñez JJ, Muñoz-Valle JF, Meza-López C, Wang LF, Machado Sulbarán AC, Torres-Hernández PC, Bedolla-Barajas M, De la O-Gómez B, Balcázar-Félix P, Hernández-Bello J. Neutralizing antibodies titers and side effects in response to BNT162b2 vaccine in healthcare workers with and without prior SARS-CoV-2 infection. Vaccines. 2021;9(7):742. doi:10.3390/vaccines9070742.
   Web of Science ®Google Scholar
• Kumar SS, Kumar A, Kirtana J, Singh AK, Shankar SH, Khan MA, Srivastava AK, Kaur R, Wig N. Risk factors and outcome among COVID-19 exposed and quarantined healthcare workers: a study on the status of existing practices of standard precautions. J Family Med Prim Care. 2020;9(10):5355–9. doi:10.4103/jfmpc.jfmpc_1579_20.
   PubMedGoogle Scholar
• Das R, Sengupta B, Goswami B, Mog C. Assessment of exposure risk among healthcare workers exposed to confirmed cases of COVID-19 working in non-COVID zones of a teaching hospital in Northeast India: a cross-sectional study. J Family Med Prim Care. 2022;11(8):4483–7. doi:10.4103/jfmpc.jfmpc_50_22.
   PubMedGoogle Scholar
• Mumma JM, Durso FT, Ferguson AN, Gipson CL, Casanova L, Erukunuakpor K, Kraft CS, Walsh VL, Zimring C, DuBose J, Centers for Disease Control and Prevention Epicenters Program, Division of Healthcare Quality Promotion, et al. Human factors risk analyses of a doffing protocol for ebola-level personal protective equipment: mapping errors to contamination. Clin Infect Dis. 2018;66(6):950–8. doi:10.1093/cid/cix957.
   PubMed Web of Science ®Google Scholar
• Psaridi L, Maltezou HC, Simonidou S, Lialliou I, Athanasopoulou D, Haila Z, Kyrimi A, Giannopoulou I, Giannousa S, Pseimada M, et al. Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection. Vaccine. 2022;40(40):5752–6. doi:10.1016/j.vaccine.2022.08.031.
   PubMed Web of Science ®Google Scholar
• Demonbreun AR, Sancilio A, Velez MP, Ryan DT, Saber R, Vaught LA, Reiser NL, Hsieh RR, D’Aquila RT, Mustanski B, et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine. 2021;38:101018. doi:10.1016/j.eclinm.2021.101018.
   PubMedGoogle Scholar
• Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal Levin E, Rubin C, Indenbaum V, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474–84. doi:10.1056/nejmoa2109072.
   PubMed Web of Science ®Google Scholar
• Brehm TT, Pfefferle S, von Possel R, Kobbe R, Nörz D, Schmiedel S, Grundhoff A, Olearo F, Emmerich P, Robitaille A, et al. SARS-CoV-2 reinfection in a healthcare worker despite the presence of detectable neutralizing antibodies. Viruses. 2021;13(4):661. doi:10.3390/v13040661.
   PubMed Web of Science ®Google Scholar
• Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, Premkumar L, Root H, van Duin D, Napravnik S, et al. Erratum for markmann et al., “Sex disparities and neutralizing-antibody durability to SARS-CoV-2 infection in convalescent individuals”. mSphere. 2021;6:e00275–21. doi:10.1128/mSphere.00736-21.
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437–42. doi:10.1038/s41586-020-2456-9.
   PubMed Web of Science ®Google Scholar
• Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, Littlefield K, Kumar S, Naik HM, Betenbaugh MJ, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141–50. doi:10.1172/JCI142004.
   PubMed Web of Science ®Google Scholar
• Yu KK, Fischinger S, Smith MT, Atyeo C, Cizmeci D, Wolf CR, Layton ED, Logue JK, Aguilar MS, Shuey K, et al. Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight. 2021;6(6):e146242. doi:10.1172/jci.insight.146242.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Auriemma RS, Pivonello C, Isidori AM, Corona G, Colao A, Millar RP. Sex disparities in COVID-19 severity and outcome: are men weaker or women stronger? Neuroendocrinology. 2021;111(11):1066–85. doi:10.1159/000513346.
   PubMed Web of Science ®Google Scholar
• Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. BioEssays. 2012;34(12):1050–9. doi:10.1002/bies.201200099.
   PubMed Web of Science ®Google Scholar
• Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine. 2008;26(29–30):3551–5. doi:10.1016/j.vaccine.2008.04.054.
   PubMed Web of Science ®Google Scholar
• Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S, Fontanini E, Bignulin S, Fornasiere E, Fumolo E, Minisini R, et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics. 2011;63(1):33–41. doi:10.1007/s00251-010-0491-7.
   PubMed Web of Science ®Google Scholar
• Schott E, Witt H, Hinrichsen H, Neumann K, Weich V, Bergk A, Halangk J, Müller T, Tinjala S, Puhl G, et al. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol. 2007;46(3):372–80. doi:10.1016/j.jhep.2006.09.011.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMoa2114583.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202(5):756–9. doi:10.1164/rccm.202001-0179LE.
   PubMed Web of Science ®Google Scholar
• Smith M, Abdesselem HB, Mullins M, Tan TM, Nel AJM, Al-Nesf MAY, Bensmail I, Majbour NK, Vaikath NN, Naik A, et al. Age, disease severity and ethnicity influence humoral responses in a multi-ethnic COVID-19 cohort. Viruses. 2021;13(5):786. doi:10.3390/v13050786.
   PubMed Web of Science ®Google Scholar
• Chen C, Liang J, Hu H, Li X, Wang L, Wang Z. Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2. Anal Biochem. 2023;673:115199. doi:10.1016/j.ab.2023.115199.
   PubMed Web of Science ®Google Scholar
• Li Q, Liu Q, Huang W, Li X, Wang Y. Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018;28(1):e1963. doi:10.1002/rmv.1963.
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerging Microbes Infect. 2020;9(1):680–6. doi:10.1080/22221751.2020.1743767.
   PubMed Web of Science ®Google Scholar
• Rajil N, Esmaeili S, Neuman BW, Nessler R, Wu HJ, Yi Z, Brick RW, Sokolov AV, Hemmer PR, Scully MO. Quantum optical immunoassay: upconversion nanoparticle-based neutralizing assay for COVID-19. Sci Rep. 2022;12(1):1263. doi:10.1038/s41598-021-03978-2.
   PubMed Web of Science ®Google Scholar
• Heggestad JT, Britton RJ, Kinnamon DS, Wall SA, Joh DY, Hucknall AM, Olson LB, Anderson JG, Mazur A, Wolfe CR, et al. Rapid test to assess the escape of SARS-CoV-2 variants of concern. Sci Adv. 2021;7(49):eabl7682. doi:10.1126/sciadv.abl7682.
   PubMed Web of Science ®Google Scholar